Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 10, 1998

View Archived Issues

Medtronic announces another merger agreement

The Medicines Company begins phase III testing of Hirulog in heart attack patients

Immune Response receives broader patent protection for RA vaccine technology

Micrologix Biotech initiates phase I trial in U.S. with MBI-226

MGI Pharma expands prostate cancer study with MGI-114

Phase II trial of diabetic neuropathy Rx commenced by Myelos

Toray discloses new epsilon opioid receptor ligands

New antitumor series developed at Daiichi

Carbostyril compounds useful for arteriosclerosis and thrombosis

Wide series of adenosine kinase inhibitors undergoing evaluation at Abbott

News from ASH: lisofylline in BMT

Orally bioavailable anti-HIV peptides described in patent literature by Japan Energy

In vitro and clinical study results support development of nitazoxanide for H. pylori infection

Preliminary indications support safety and efficacy of 90Y-labeled lintuzumab in AML

Pfizer produces novel erythromycins using precursor-directed biosynthetic technology

Broad-spectrum, water-soluble antiviral agent produced by Streptomyces discovered in Japan

New imaging agent using AnorMED technology begins phase III trials

Avigen presents results of preclinical testing of hemophilia gene therapy and plans clinical trials

HBV DNA vaccine elicits protective immune response in humans for first time

Combination tablet that eases pill burden in HIV therapy now available in Canada

ImClone's anti-KDR antibody, a novel angiogenesis inhibitor, featured at ASH

Idec further defines clinical usage of IDEC-Y2B8

Canadian approval obtained for first chickenpox vaccine

The FDA approves lamivudine for the treatment of chronic HBV

Thalidomide evaluated for toxic epidermal necrolysis and found detrimental

Biological activity of ZD-7944 characterized in vitro and in animals

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...